Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0.0154462242562929
Stock impact report

Verona Pharma reports Q3 results Nov. 04, 2024 2:06 AM ET By: Manshi Mamtora , CFA [Seeking Alpha]

Verona Pharma plc - American Depositary Shares (VRNA) 
US:NASDAQ Investor Relations: nasdaq.com/symbol/vrna/real-time
Company Research Source: Seeking Alpha
Cash and cash equivalents at September 30, 2024 were $336.0 million (December 31, 2023: $271.8 million). More on Verona Pharma Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care Verona Pharma: A Post FDA Approval Analysis Verona Pharma plc (VRNA) Q2 2024 Earnings Call Transcript Verona Pharma Q3 2024 Earnings Preview Verona started at overweight by Wells Fargo, says COPD drug undervalued Recommended For You Comments More Trending News Show less Read more
Impact Snapshot
Event Time:
VRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for VRNA alerts
Opt-in for
VRNA alerts

from News Quantified
Opt-in for
VRNA alerts

from News Quantified